Previous Year's Programs
View speakers, slides, and presentations from previous year's symposiums.
*This program was developed independently by the Barbara Davis Center for Diabetes and supported in part by an educational grant from Sanofi US.
9th Symposium on General Population Screening for T1D
November 9-10, 2026
Barbara Davis Center for Diabetes
The symposium aims to explore the expanding evidence and current international efforts to identify pre-symptomatic T1D, emphasizing the potential benefits such as delayed progression and prevention of complications. Through expert panels and case studies, the event will also address the challenges of monitoring and supporting children with early-stage T1D, as well as the combined screening for both T1D and celiac disease. The discussions will conclude with future directions for screening, highlighting the need for coordinated efforts and policy guidance.
Location: Anschutz Health Sciences Building
1890 N Revere Ct, Aurora, CO 80045
- Jointly provided by Postgraduate Institute for Medicine and Barbara Davis Center for Diabetes
- This activity is supported by an independent educational grant from Sanofi.
Target Audience: Healthcare professionals including MD, DO, advanced practice providers, nurses, pharmacists, social workers, and dieticians; researchers in the area of screening, monitoring, and prevention of diabetes; lay representatives of patient organizations and representatives of funding agencies.
Learning Objectives:
1) Review the latest consensus guidelines and global evidence supporting early detection and screening for stage 1 and 2 type 1 diabetes (T1D) in the general population.
2) Explain advancements in islet autoantibody screening methods, including laboratory techniques and strategies for staging and risk stratification.
3) Explain best practices for confirming positive screening results and communicating findings to families and patients.
4) Discuss emerging interventions, clinical trials, and implementation strategies aimed at delaying or preventing progression to symptomatic T1D.
5) Collaborate with interdisciplinary teams to address challenges in screening implementation, patient monitoring, and integration into clinical workflows across healthcare systems.
*Open to all Anschutz Medical Campus faculty and staff.
Please use this link for questions
Disclosure of Financial Relationships
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified financial relationships are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The PIM planners and others have nothing to disclose.
Faculty and relevant financial relationships:
| Faculty | Organization | Disclosures |
|---|---|---|
| Peter Achenbach, MD | Institute of Diabetes Research, Helmholtz Munich, Munich, Germany | Sanofi (Consultant/Advisory Board), Sanofi (Speakers Bureau/Honoraria) |
| Rick Bacher | GetStirredUp | None |
| Melanie Batchelor, MHS | Beyond T1D | None |
| Kimberly Bautista, MPH | Barbara Davis Center for Diabetes | None |
| Hali Broncucia, MS | Barbara Davis Center for Diabetes | None |
| Carmella Evans-Molina, MD, PhD | Indiana University School of Medicine | Integrated Nanotherapeutics, Isla Technologies, DiogenyX, Neurodon, Sanofi (Consultant/Advisory Board) |
| Dan Feiten, MD | Office Practicum | None |
| Lauric Ferrat | University of Geneva | Sanofi (Speakers Bureau/Honoraria, Consultant/Advisory Board) Breakthrough T1D, Helmsley, Fondation du Diabète (Grant/Research Support) |
| Brigitte I. Frohnert, MD, PhD | Barbara Davis Center for Diabetes | None |
| Katie Gelman | None listed | None |
| Patricia Gesualdo, MSPH | Barbara Davis Center for Diabetes | None |
| Kurt J. Griffin | Benaroya Institute | Sanofi, SAB Biotherapeutics, COUR Pharma (Grant/Research Support - site investigator for clinical trials) |
| Zehra Haider | None listed | None |
| Robin Hayeems, PhD | Hospital for Sick Children | None |
| Grace Herod | Helmsley Charitable Trust | None |
| Laura Jacobsen, MD | University of Florida | Sanofi (Consultant/Advisory Board) |
| Raquel Lopez Diez, PhD | Breakthrough T1D | None |
| Julianne Lally | None listed | None |
| Robert McQueen | University of Colorado Anschutz | Sanofi, Stage Analytics, Merck, Institute for Clinical and Economic Review (Consultant/Advisory Board) |
| Martha Middlemist, MD | Pediatrics 5280, Centennial, CO | None |
| Holly O'Donnell, PhD | Barbara Davis Center for Diabetes, University of Colorado Anschutz | NIDDK, Breakthrough T1D (Grant/Research Support) Stock Ownership: Eli Lilly & Company, Johnson & Johnson, Merck & Co., Sanofi (Speakers Bureau, Consultant/Advisory Board) |
| Marian Rewers, MD, PhD | Barbara Davis Center for Diabetes, University of Colorado | Sanofi (Grant/Research Support, Consultant/Advisory Board) Vertex (Consultant/Advisory Board) |
| Katie Schafer,DO | Bloom Pediatrics | None |
| Kimber Simmons, MD | Barbara Davis Center for Diabetes | Sanofi, Mannkind (Consultant/Advisory Board) Breakthrough T1D, Enable Biosciences, NIH (NIDDK), Op-T-Mune (Grant/Research Support) |
| Emily Sims, MD | Indiana University School of Medicine / IU Health | Sanofi (Grant/Research Support) Sanofi, Wink Therapeutics, Diamyd, Strafluence (Consultant/Advisory Board) Sanofi Med Learning (Speakers Bureau/Honoraria) Stock Ownership: Wink Therapeutics |
| Laura Smith | None listed | None |
| Andrea Steck | Barbara Davis Center for Diabetes | Lilly, Dompe (Grant/Research Support) Sanofi (Consultant/Advisory Board) |
| Zdeněk Šumník | Motol University Hospital, Prague, Czechia | Sanofi (Speakers Bureau/Honoraria), Consultant/Advisory Board) |
| Clive Wasserfall, MD | University of Florida | None |
| Kupper Wintergerst, MD, MBA | University of Louisville | Sanofi (Speakers Bureau/Honoraria, Consultant/Advisory Board) |
| Liping Yu, MD | Barbara Davis Center for Diabetes | None |
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Barbara Davis Center. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this live activity for a maximum of 14.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 14.5 contact hours.
Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 14.5 contact hour(s) (1.45 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number - JA4008162-9999-26-568-L99-P )
Type of Activity: Knowledge
(**Credit hours are subject to change based on the final review and approval of course content and instructional materials. **)
Americans with Disabilities Act (required for live meetings only)
Event staff will be glad to assist you with any special needs (i.e., physical, dietary, etc). Please contact Christy Vasey prior to the live event at (303) 724-9787 or email [email protected].
Fee Information
No fee